CompletedPhase 4

Assessment of the Effect of Vitamin C on Anemia in Patients With Continuous Ambulatory Peritoneal Dialysis

66 participantsStarted 2011-11

Plain-language summary

Among patients with chronic kidney disease (CKD), there is association between anemia and increased chance of mortality mainly because of cardiovascular diseases and stroke, risk of hospitalization, and death prevalence in predialysis patients. Vitamin C plays an important role in iron metabolism and application for red blood cell formation. Infusion of ascorbate supplementation can reduce oxidative stress among hemodialysis patients. This study aimed to assess the effect of vitamin C on patients with continuous ambulatory peritoneal dialysis (CAPD).

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Long-term treatment of PD (at least more than three months)
✓. Hemoglobin less than 15 milligrams per liter
✓. Age over 18 years
✓. vitamin c level less than 4microgram\\ml

Exclusion criteria

✕. Acute illness (including infectious diseases and cancer) within 3 months prior to determining the level of vitamin C
✕. Any recent blood transfusion, recurrent bleeding or hemolysis
✕. Supplementation with vitamin C) during the 3 weeks prior to the determination of serum levels 4 -Consumption of tetracycline, antacid and Cholestyramine

What they're measuring

level of vitamin c hemoglobin

Timeframe: six weeks prescription

Trial details

NCT IDNCT02780505

SponsorShiraz University of Medical Sciences

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2012-04

View on ClinicalTrials.gov More Anemia trials